Aekrungrueangkit, C.; Wangngae, S.; Kamkaew, A.; Ardkhean, R.; Thongnest, S.; Boonsombat, J.; Ruchirawat, S.; Khotavivattana, T. Novel Psoralen Derivatives as Anti-breast Cancer Agents and Their Light-Activated Cytotoxicity Against HER2 Positive Breast Cancer Cells. Sci. Rep. 2022, 12, 13487.

05 Aug 2022
0

Aekrungrueangkit, C.; Wangngae, S.; Kamkaew, A.; Ardkhean, R.; Thongnest, S.; Boonsombat, J.; Ruchirawat, S.; Khotavivattana, T. Novel Psoralen Derivatives as Anti-breast Cancer Agents and Their Light-Activated Cytotoxicity Against HER2 Positive Breast Cancer Cells. Sci. Rep. 2022, 12, 13487.

Tags

Share this

Related Posts

Svasti, J.; Srisomsap, C.; Subhasitanont, P.; Keeratichamroen, S.; Chokchaichamnankit, D.; Ngiwsara, L.; Chimnoi, N.; Pisutjaroenpong, S.; Techasakul, S.; Chen, S. T. Proteomic Profiling of Cholangiocarcinoma Cell Line Treated with Pomiferin from Derris malaccensis. Proteomics 2005, 5, 4504-4509.
Anukanon, S.; Pongpamorn, P.; Tiyabhorn, W.; Chatwichien, J.; Niwetmarin, W.; Sessions, R. B.; Ruchirawat, S.; Thasana, N. In silico-guided Rational Drug Design and Semi-synthesis of C(2) Functionalized Huperzine A Derivatives as Acetylcholinesterase Inhibitor. ACS Omega 2021, 6, 19924–19939.

Recent Posts